Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Low level of dopaminergic D2 receptor binding in obsessive-compulsive disorder.

Denys D, van der Wee N, Janssen J, De Geus F, Westenberg HG.

Biol Psychiatry. 2004 May 15;55(10):1041-5.

PMID:
15121489
2.

Reduced striatal dopamine D2/3 receptor availability in Body Dysmorphic Disorder.

Vulink NC, Planting RS, Figee M, Booij J, Denys D.

Eur Neuropsychopharmacol. 2016 Feb;26(2):350-6. doi: 10.1016/j.euroneuro.2015.11.018. Epub 2015 Nov 30.

PMID:
26711686
3.

Dopamine D1 receptor binding in the striatum of patients with obsessive-compulsive disorder.

Olver JS, O'Keefe G, Jones GR, Burrows GD, Tochon-Danguy HJ, Ackermann U, Scott A, Norman TR.

J Affect Disord. 2009 Apr;114(1-3):321-6. doi: 10.1016/j.jad.2008.06.020. Epub 2008 Aug 15.

PMID:
18706700
4.

Dopamine transporter density of basal ganglia assessed with [123I]IPT SPET in obsessive-compulsive disorder.

Kim CH, Koo MS, Cheon KA, Ryu YH, Lee JD, Lee HS.

Eur J Nucl Med Mol Imaging. 2003 Dec;30(12):1637-43. Epub 2003 Sep 25.

PMID:
14513291
5.

Striatal dopamine D(2) receptor availability in OCD with and without comorbid social anxiety disorder: preliminary findings.

Schneier FR, Martinez D, Abi-Dargham A, Zea-Ponce Y, Simpson HB, Liebowitz MR, Laruelle M.

Depress Anxiety. 2008;25(1):1-7.

PMID:
17252580
6.

Enhanced dopamine transporter density in psychotropic-naive patients with obsessive-compulsive disorder shown by [123I]{beta}-CIT SPECT.

van der Wee NJ, Stevens H, Hardeman JA, Mandl RC, Denys DA, van Megen HJ, Kahn RS, Westenberg HM.

Am J Psychiatry. 2004 Dec;161(12):2201-6.

PMID:
15569890
7.

Dopamine transporter density in the basal ganglia in obsessive-compulsive disorder, measured with [123I]IPT SPECT before and after treatment with serotonin reuptake inhibitors.

Kim CH, Cheon KA, Koo MS, Ryu YH, Lee JD, Chang JW, Lee HS.

Neuropsychobiology. 2007;55(3-4):156-62. Epub 2007 Jul 26.

PMID:
17657168
8.

Dopaminergic activity in Tourette syndrome and obsessive-compulsive disorder.

Denys D, de Vries F, Cath D, Figee M, Vulink N, Veltman DJ, van der Doef TF, Boellaard R, Westenberg H, van Balkom A, Lammertsma AA, van Berckel BN.

Eur Neuropsychopharmacol. 2013 Nov;23(11):1423-31. doi: 10.1016/j.euroneuro.2013.05.012. Epub 2013 Jul 19.

9.

Alteration of dopamine D2/D3 receptor binding in patients with juvenile myoclonic epilepsy.

Landvogt C, Buchholz HG, Bernedo V, Schreckenberger M, Werhahn KJ.

Epilepsia. 2010 Sep;51(9):1699-706. doi: 10.1111/j.1528-1167.2010.02569.x.

10.

Caudate nucleus abnormalities in obsessive-compulsive disorder: measurements of MRI signal intensity.

Calabrese G, Colombo C, Bonfanti A, Scotti G, Scarone S.

Psychiatry Res. 1993 Jun;50(2):89-92.

PMID:
8378491
11.

Fluvoxamine treatment and D2 receptors: a pet study on OCD drug-naïve patients.

Moresco RM, Pietra L, Henin M, Panzacchi A, Locatelli M, Bonaldi L, Carpinelli A, Gobbo C, Bellodi L, Perani D, Fazio F.

Neuropsychopharmacology. 2007 Jan;32(1):197-205. Epub 2006 Oct 4.

12.

Patients with obsessive-compulsive disorder have increased 5-HT2A receptor binding in the caudate nuclei.

Adams KH, Hansen ES, Pinborg LH, Hasselbalch SG, Svarer C, Holm S, Bolwig TG, Knudsen GM.

Int J Neuropsychopharmacol. 2005 Sep;8(3):391-401. Epub 2005 Apr 1.

PMID:
15801987
13.
14.

Normal caudate nucleus in obsessive-compulsive disorder assessed by quantitative neuroimaging.

Aylward EH, Harris GJ, Hoehn-Saric R, Barta PE, Machlin SR, Pearlson GD.

Arch Gen Psychiatry. 1996 Jul;53(7):577-84. Review.

PMID:
8660124
15.

Dopamine type-1 receptor binding in major depressive disorder assessed using positron emission tomography and [11C]NNC-112.

Cannon DM, Klaver JM, Peck SA, Rallis-Voak D, Erickson K, Drevets WC.

Neuropsychopharmacology. 2009 Apr;34(5):1277-87. doi: 10.1038/npp.2008.194. Epub 2008 Oct 22.

16.

Imaging of dopamine transporters and D2 receptors in patients with Parkinson's disease and multiple system atrophy.

Knudsen GM, Karlsborg M, Thomsen G, Krabbe K, Regeur L, Nygaard T, Videbaek C, Werdelin L.

Eur J Nucl Med Mol Imaging. 2004 Dec;31(12):1631-8. Epub 2004 Jul 22.

PMID:
15583914
17.

Striatal dopamine-2 receptor occupancy in psychotic patients treated with risperidone.

Küfferle B, Brücke T, Topitz-Schratzberger A, Tauscher J, Gössler R, Vesely C, Asenbaum S, Podreka I, Kasper S.

Psychiatry Res. 1996 Nov 25;68(1):23-30.

PMID:
9027930
18.

[123]IBZM binding predicts dopaminergic responsiveness in patients with parkinsonism and previous dopaminomimetic therapy.

Schwarz J, Tatsch K, Gasser T, Arnold G, Oertel WH.

Mov Disord. 1997 Nov;12(6):898-902.

PMID:
9399212
19.

Dementia with lewy bodies: a study of post-synaptic dopaminergic receptors with iodine-123 iodobenzamide single-photon emission tomography.

Walker Z, Costa DC, Janssen AG, Walker RW, Livingstone G, Katona CL.

Eur J Nucl Med. 1997 Jun;24(6):609-14.

PMID:
9169566
20.

Dopamine D(1) receptor binding in the anterior cingulate cortex of patients with obsessive-compulsive disorder.

Olver JS, O'Keefe G, Jones GR, Burrows GD, Tochon-Danguy HJ, Ackermann U, Scott AM, Norman TR.

Psychiatry Res. 2010 Jul 30;183(1):85-8. doi: 10.1016/j.pscychresns.2010.04.004. Epub 2010 Jun 9.

PMID:
20538439

Supplemental Content

Support Center